Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05.

8593 Background: Brain metastases (mets) occur frequently in pts with NSCLC, particularly pts with certain AGAs, and indicate poor prognosis. For pts with AGAs, treatment options are limited once targeted therapy and platinum-based chemotherapy (Pt-CT) become ineffective. The phase 2 TROPION-Lung05 trial (NCT04484142) of Dato-DXd has demonstrated systemic efficacy and a manageable safety profile in heavily pretreated pts with a/m NSCLC with AGAs who progressed following targeted therapy and Pt-CT; here we report an exploratory analysis of intracranial (IC) efficacy. Methods: Pts were treated with Dato-DXd 6 mg/kg IV Q3W. Pts with clinically stable brain mets were eligible. IC responses were assessed by blinded independent central review (BICR) of cranial CT/MRI (CNS BICR; per CNS RECIST) at baseline (BL) and Q6W. Systemic objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR, defined as CR+PR+SD or non-CR/non-PD lasting ≥6 mo), progression-free survival (PFS) by BICR per RECIST 1.1 and treatment-related adverse events (TRAEs) were determined in pts with and without BL brain mets. Results: In total 53/137 (39%) treated pts had BL brain mets; 29/53 (55%) had an EGFRmutation. Pts with BL brain mets had a median (range) of 3 (2–6) prior systemic therapies in the a/m setting, including targeted therapy and Pt-CT with/without immune checkpoint inhibitors; 15/53 (28%) had untreated brain mets. At data cutoff (Dec 14, 2022), median (range) study and treatment durations among pts with BL brain mets were 14.8 (9.7–20.5) and 3.2 (0.7–17.2) mo, respectively. Of these pts, 18/53 (34%) had measurable IC target lesions (3 untreated) and 35/53 (66%) had only non-target IC lesions. In 18 pts with target lesions, IC ORR was 22% (95% CI, 6–48), including 1 of 3 pts with untreated target lesions; IC DCR was 72% (95% CI, 47–90); IC CBR was 44% (95% CI, 22–69). Reduction in the sum of diameters of brain lesions was seen in 10/18 (56%). Median time to IC response was 1.5 (range, 1.3–5.4) mo; median duration of IC response was 5.5 (95% CI, 3.4–NE) mo Systemic efficacy and safety were similar in pts with and without BL brain mets (Table). Conclusions: Dato-DXd showed encouraging IC activity consistent with systemic responses in pts with a/m NSCLC with AGAs, supporting further investigation of Dato-DXd in pts with brain mets. Clinical trial information: NCT04484142 . Table: see text